MedTrace Logo

Clinical Study to Investigate Visual Performance of IOL: FineVision HP

NCT03027024 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2021-05-06

No results posted yet for this study

Summary

This is a prospective, non-randomised, controlled, single-surgeon, single-center post-market clinical follow up study whereby patient undergoing routine cataract surgery will have bilateral implantation of a recently introduced TGA (Therapeutics Goods Authority, Australia) approved trifocal intraocular lens FineVision Evo (PhysIOL, Liège, Belgium). The primary and secondary effectiveness data for visual acuity, defocus curves, contrast sensitivity and any adverse events will be collected.

Conditions

  • Cataract
  • Lens Opacity

Interventions

DEVICE

Implantation of IOL: PhysIOL POD F GF

Implantation of trifocal IOL POD F GF consisting of hydrophobic material

Sponsors & Collaborators

  • Beaver-Visitec International, Inc.

    lead INDUSTRY

Principal Investigators

  • Uday Bhatt, MD · Vision Eye Institute - Footscray

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-02-27
Primary Completion
2018-10-22
Completion
2018-10-22

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03027024 on ClinicalTrials.gov